Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
Safety and Efficacy of TSHA-102 in Pediatric Females with Rett Syndrome (REVEAL Pediatric Study)
NCTID
NCT06152237
(View at clinicaltrials.gov)
Description
The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study duration is up to 6 years.
(Show More)
Development Status
Active
Indication
Rett Syndrome
Disease Ontology Term
DOID:1206
Compound Name
TSHA-102
Sponsor
Taysha Gene Therapies, Inc.
Funder Type
Industry
Recruitment Status
Recruiting
Enrollment Count
20
Results Posted
Not Available
Therapy Information
Target Gene/Variant
MiniMECP2
Therapy Type
Gene transfer
Therapy Route
In-vivo
Mechanism of Action
Functional gene replacement
Route of Administration
Intrathecal
Drug Product Type
Viral vector
Target Tissue/Cell
Delivery System
Viral transduction
Vector Type
scAAV9
Editor Type
none
Dose 1
5.7E14 vg (n=4)
Dose 2
1E15 vg (n=6)
Dose 3
Dose 4
Dose 5
Study Record Dates
Current Stage
Phase1, Phase2
Submit Date
2023-11-21
Completion Date
2031-11-02
Last Update
2024-11-12
Participation Criteria
Eligible Age
5 Years - 8 Years
Standard Ages
Child
Sexes Eligible for Study
FEMALE
Locations
No.of Trial Sites
10
Locations
Canada,United States,United Kingdom
Regulatory Information
Has US IND
True
FDA Designations
Fast Track, Orphan Drug Designation, Rare Pediatric Disease Designation, Regenerative Medicine Advanced Therapy
Recent Updates
Update on pivotal trial design expected in 1H2025
Resources/Links
Clinical Publications
(Corporate Presentation) November 2024
(Corporate Presentation) TSHA-102 in clinical evaluation for Rett syndrome: Cohort one data from the REVEAL Phase 1/2 Adolescent-Adult and Pediatric trials - June 2024
News and Press Releases
SEC Form 10-K: Taysha Gene Therapies, Inc. FY2024
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Preclinical Publications
The Efficacy of a Human-Ready mini MECP2 Gene Therapy in a Pre-Clinical Model of Rett Syndrome
Related NCTID
Phase 1/2: NCT05606614 (Adolescent and adult cohorts)